PFBT
AVBP icon

Parkside Financial Bank & Trust’s ArriVent BioPharma AVBP Stock Holding History

Parkside Financial Bank & Trust’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-20
Closed -$370 – 3017
2025
Q1 		$370 Buy
+20
New +$489 ﹤0.01% 2582

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Parkside Financial Bank & Trust's AVBP Position: Q2 2025 in Review

Parkside Financial Bank & Trust sold out of ArriVent BioPharma (AVBP) in Q2 2025, closing a stake of 20 shares — an estimated $370 sold.

Parkside Financial Bank & Trust first reported a position in AVBP in Q1 2025 and held it in 1 quarter. The position peaked at $370 in Q1 2025. 99 funds tracked by Wall St. Rank hold AVBP as of Q2 2025.

  • Parkside Financial Bank & Trust reported no remaining ArriVent BioPharma position as of Q2 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 20 ArriVent BioPharma shares in Q2 2025, an estimated $370.
  • Parkside Financial Bank & Trust first reported a position in ArriVent BioPharma in Q1 2025 and held it in 1 quarter.
  • Parkside Financial Bank & Trust's ArriVent BioPharma position peaked at $370 in Q1 2025.
  • 99 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2025, filed 7 Aug 2025.